AJR Join ARRS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lindsay, M. J.
Right arrow Articles by Coleman, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lindsay, M. J.
Right arrow Articles by Coleman, R. E.
DOI:10.2214/AJR.06.1175
AJR 2007; 188:1109-1113
© American Roentgen Ray Society


Perspective

The National Oncologic PET Registry: Expanded Medicare Coverage for PET Under Coverage with Evidence Development

Matthew J. Lindsay1, Barry A. Siegel2, Sean R. Tunis3, Bruce E. Hillner4, Anthony F. Shields5, Brian P. Carey1 and R. Edward Coleman6

1 Foley Hoag, LLP, 155 Seaport Blvd., Boston, MA 02210-2600.
2 Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO.
3 HealthTech, San Francisco, CA.
4 Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA.
5 Karmanos Cancer Institute, Wayne State University, Detroit, MI.
6 Department of Radiology, Duke University School of Medicine, Durham, NC.

Abstract

OBJECTIVE. The purpose of this article is to review the recent expansion of Medicare coverage for 18F-FDG PET for certain cancer indications under the Centers for Medicare & Medicaid Services' new Coverage with Evidence Development (CED) policy and to describe the specific operational mechanics of the National Oncologic PET Registry (NOPR).

CONCLUSION. The NOPR will make possible a more accurate assessment of the actual influence of PET on patient management across a wide spectrum of cancer indications. By linking access to PET for virtually all Medicare beneficiaries to the collection of clinically valuable evidence, the NOPR represents the cutting edge of the CED approach.

Keywords: cancer • National Oncologic PET Registry • nuclear medicine • oncologic imaging • PET • PET/CT




This article has been cited by other articles:


Home page
JCOHome page
B. E. Hillner, B. A. Siegel, D. Liu, A. F. Shields, I. F. Gareen, L. Hanna, S. H. Stine, and R. E. Coleman
Impact of Positron Emission Tomography/Computed Tomography and Positron Emission Tomography (PET) Alone on Expected Management of Patients With Cancer: Initial Results From the National Oncologic PET Registry
J. Clin. Oncol., May 1, 2008; 26(13): 2155 - 2161.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
B. E. Hillner, D. Liu, R. E. Coleman, A. F. Shields, I. F. Gareen, L. Hanna, S. H. Stine, and B. A. Siegel
The National Oncologic PET Registry (NOPR): Design and Analysis Plan
J. Nucl. Med., November 1, 2007; 48(11): 1901 - 1908.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Roentgen Ray Society.